We tested the activity of LY146032 (LY) against 57 strains of enterococci collected from Chile, Thailand, and the United States. Some of the strains were resistant to high levels of gentamicin or streptomycin (or both), and two produced beta-lactamase (Bla'). MICs of LY ranged from 0.5 to 8 ,Ig/ml, and MBCs ranged from 1 to 64 p.g/ml. In time-kill assays, a 2 to 3 log10 killing effect was observed with LY against two Bla+ strains of Streptococcus (Enterococc*s) faecalis and against three strains that were highly resistant to streptomycin and gentamicin. Synergism was demonstrated with LY and streptomycin against a Bla+ strain lacking high-level streptomycin resistance. These in vitro results suggest that LY should be studied further for possible use in treatment of enterococcal infections. LY146032 (LY), a new lipopeptide compound that inhibits bacterial cell wall synthesis (1), has recently been shown to have good activity against enterococci, with MICs ranging from 0.25 to 8 ,ug/ml and MBCs near the MICs for the enterococci tested (2, 3, 13) . This is potentially significant since an increasing number of enterococci have been found to be resistant to high levels of all aminoglycosides and are thus resistant to penicillin-aminoglycoside synergism (5, 9, 14) . Two penicillinase-producing strains of Streptococcus (Enterococcus) faecalis have recently been identified (7, 8) , further complicating the therapy of enterococcal infections. In this study, we determined the inhibitory and bactericidal activity of LY against two penicillinase-producing enterococci and other enterococci with and without high-level aminoglycoside resistance that were isolated from three distinct geographic locations.
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MATERIALS AND METHODS
Bacterial strains. Enterococci highly resistant (MIC, >2,000 pug/ml) to streptomycin only (Smr) (21 strains), gentamicin only (Gmr) (1 strain), both gentamicin and streptomycin (30 strains), or neither (5 strains) were collected from Santiago, Chile; Bangkok, Thailand; and Houston, Tex. All of the Gmr strains were identified as S. faecalis with the API 20S system (Analytab Products, Plainview, N.Y.). Strain PA is a clinical isolate of S. faecalis which is highly resistant to all aminoglycosides and produces penicillinase (Bla+) (4, 7) . Strain 67 x 22 is a Gmr Bla+ transconjugant derived from mating strain HH22 (8) with enterococcal strain 67, a rifampin-and fusidic acid-resistant derivative of a clinical enterococcal isolate; this Bla+ transconjugant is not highly Smr and therefore was used instead of strain HH22 in synergy experiments. Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923, and Streptococcus pyogenes ATCC 19615 were also included.
Susceptibility testing and synergy studies. MICs were determined by broth micro-and macrodilution methods according to the protocol of the National Committee for Time-kill and synergy experiments were performed according to the procedure described by Moellering et al. (6) with Mueller-Hinton broth supplemented with 50 ,ug of calcium per ml. Penicillin (10 U/ml), streptomycin (20 ,ug/ml), and vancomycin, imipenem, and LY (10 jig/ml each) were used. Samples were removed and serially diluted, and 100 ,ul of the appropriate dilutions was spread onto the entire surface of a brain heart infusion agar plate which was then incubated for 48 h at 37°C. Assuming maximal plating efficiency, the minimum number of detectable CFU per milliliter would be 10. Lack of antibiotic carry-over was demonstrated as outlined above.
RESULTS AND DISCUSSION LY MICs and MBCs for enterococcal strains. The geometric mean MIC of LY for the 57 strains tested by agar dilution was 2.5 ug/mnl with a range of 0.5 to 8 ,ug/ml. The geometric mean MIC for the 18 strains tested by microdilution was 3.2 ,ug/ml with the same range as given above. Twelve strains were tested by macrodilution, and the geometric mean MIC was 1.2 ,ug/ml (range, 0.25 to 8 ,ug/ml). These results concur with those previously obtained for enterococci (2, 3, 13 ). For 12 strains tested by all three methods, the MICs for 50 and 90% of these strains were, respectively, 2 and 4 ,ug/ml by strains highly resistant to all aminoglycosides, for which there is no standard regimen that is bactericidal.
